Posts by rw-admin

Jerusalem-based Teva Pharmaceuticals’ sensor-packed, app-connected digital inhaler has recently received marketing approval from the US FDA, according to a release from the company. The device will first become available next year through a “small number” of healthcare system pilot partnerships, with a full national launch currently planned for 2020. Teva’s ProAir Digihaler is indicated for…

Nearly a year after bagging the option to acquire Millipede, Boston Scientific has pulled the trigger. When the pair inked the agreement in January, Boston Scientific handed over $90 million for a portion of the mitral regurgitation startup’s shares. Now, the devicemaker is paying $325 million to pick up the rest of Millipede’s shares. The deal was…

Acorda Therapeutics said this week that the FDA approved its Inbrija device for the intermittent treatment of  “off” episodes in people with Parkinson’s disease. The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low levels of dopamine between doses of the standard oral Parkinson’s therapy,…

Women who experience false-positive mammograms are at an increased risk of breast cancer for more than a decade, according to new research published in the British Journal of Cancer. The authors collected data from more than 1.1 million women from three population-based screening programs—one from Denmark, one from Norway and one from Spain—for the study. Patients were between…

GE Healthcare reportedly filed confidentially for an initial public offering as it readies a spinout of its GE Healthcare business. The Boston-based industrial giant tapped Goldman Sachs, Bank of America, Citigroup, JPMorgan Chase and Morgan Stanley for help with the flotation, according to Bloomberg, which cited sources “who asked not to be identified as the details…